Evidence map›Paper›PMID 23299761›Full record

Trial reportMedicine and science in sports and exercise2013

Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients.

Joshua S Wooten, Preethi Nambi, Baiba K Gillard, Henry J Pownall, Ivonne Coraza, Lynne W Scott, Vijay Nambi, Christie M Ballantyne, Ashok Balasubramanyam

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Medicine and science in sports and exercise, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Atorvastatin Decreased Circulating RANTES Levels in Impaired Glucose Tolerance Patients with Hypercholesterolemia: An Interventional Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2017
    Article
  6. PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia.Medical science monitor : international medical journal of experimental and clinical research · 2016
    Article
  7. A Review of Management of Inflammation in the HIV Population.BioMed research international · 2016 · on this map
    Review
  8. Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection.Endocrinology and metabolism clinics of North America · 2014
    Review
  9. Article
  10. A literature review on cardiovascular risk in human immunodeficiency virus-infected patients: implications for clinical management.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Joshua S WootenDivision of Atherosclerosis and Vascular Biology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Preethi Nambi
Baiba K Gillard
Henry J Pownall
Ivonne Coraza
Lynne W Scott
Vijay Nambi
Christie M Ballantyne
Ashok Balasubramanyam
Baylor College of Medicine · USInstitute for Atherosclerosis Research · RUHouston Methodist · US

Funding

Diabetes Endocrinology Research CenterP30DK079638 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI CHAN, LAWRENCE · 2008 to 2012
$6.4M
Therapeutic Approaches to Dysregulated HDL MetabolismR01HL056865 · NHLBI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI POWNALL, HENRY J. · 1997 to 2015
$5.2M
ATHEROSCLEROSIS AND VASCULAR BIOLOGY TRAINING CENTERT32HL007812 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI BALLANTYNE, CHRISTIE MITCHELL · 1997 to 2012
$3.4M
ENZYMIC REACTIONS OF MODEL PLASMA LIPOPROTEINSR01HL030914 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI POWNALL, HENRY J. · 1985 to 2010
$2.2M
Diet/Exercise, Niacin, Fenofibrate for HIV LipodystrophyR01HL073696 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI BALASUBRAMANYAM, ASHOK · 2003 to 2008
$1.5M
NHLBI NIH HHS HL56865NHLBI NIH HHS R01 HL030914NHLBI NIH HHS R01 HL056865NHLBI NIH HHS R01 HL073696NHLBI NIH HHS R01 HL30914NHLBI NIH HHS R01 HL73696NHLBI NIH HHS T32 HL007812NHLBI NIH HHS T32 HL07812NIDDK NIH HHS P30 DK079638NIDDK NIH HHS P30DK079638
6 · The paper itself

Abstract

purposePatients with dyslipidemia associated with HIV-1 infection and highly active antiretroviral therapy (HAART) have elevated levels of Lp-PLA2 and CCL5/regulated on activation, normal T-cell expressed and secreted (RANTES), which may increase the risk of cardiovascular disease. PURPOSE: This study aimed to determine whether an intensive diet and exercise (D/E) program, independently or combined with fenofibrate or niacin, could reduce Lp-PLA2 or RANTES.

methodsPatients with hypertriglyceridemic HIV on stable HAART (n = 107) were randomized to one of five interventions: 1) usual care, 2) D/E with placebos, 3) D/E with fenofibrate and placebo, 4) D/E with niacin and placebo, or 5) D/E with fenofibrate and niacin for 24 wk. Lp-PLA2 and RANTES concentrations were measured in fasting plasma samples at baseline and postintervention. General linear models were used to compare Lp-PLA2 and RANTES levels between the five groups postintervention, controlling for baseline levels, age, body mass index, CD4 T-cell count, viral load, duration of infection, and HAART.

resultsAt baseline, fasting plasma Lp-PLA2 (388.5 ± 127.5 ng·mL) and RANTES (43.8 ± 25.5 ng·mL) levels were elevated when compared with healthy controls. Posttreatment Lp-PLA2 mass was lower in patients who received D/E only (323.0 ± 27.2 ng·mL), D/E plus fenofibrate (327.2 ± 25.9 ng·mL), and D/E plus niacin (311.1 ± 27.8 ng·mL) when compared with patients receiving usual care (402.2 ± 25.3 ng·mL). RANTES concentrations were not significantly affected by any intervention.

conclusionsElevated plasma Lp-PLA2 mass can be reduced by an intensive D/E program in patients with HIV/HAART-associated dyslipidemia. RANTES is elevated but is not reduced by lifestyle modification, fenofibrate, or niacin.

Indexed as

Antiretroviral Therapy, Highly ActiveDiet TherapyExercise TherapyHIV-11-Alkyl-2-acetylglycerophosphocholine EsteraseAdultAgedBiomarkersChemokine CCL5Combined Modality TherapyDouble-Blind MethodDrug Administration ScheduleFemaleFenofibrateHIV InfectionsHumans1-Alkyl-2-acetylglycerophosphocholine EsteraseBiomarkersCCL5 protein, humanChemokine CCL5FenofibrateHypolipidemic AgentsNiacin

Identifiers

PMID23299761
PMCPMC3655089
OpenAlexW2161924170

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.